August 2012
-
According to ARS Pharmaceuticals, the EMA has accepted the company’s marketing authorization application for its Neffy (ARS-1) epinephrine nasal spray for the emergency treatment of anaphylaxis. ARS recently announced that Recordati had acquired marketing rights… Read more . . .
-
US-based startup Kinaset Therapeutics has signed a licensing and develop an inhaled pan-JAK inhibitor that was in Vectura’s pipeline prior to that company’s transformation into an inhalation CDMO. In July 2019, Vectura announced that it… Read more . . .
-
Dr. Reddy’s Laboratories said that it has acquired several mometasone and mometasone/azelastine nasal sprays for the treatment of seasonal and perennial allergic rhinitis from Glenmark for Russia, Kazakhstan, Uzbekistan, and Ukraine. The brands included in… Read more . . .
-
Nanoform Finland has announced the launch of new nanonization technology that is capable of creating biological nanoparticles down to 50 nm. The company said that it has filed for US patents covering the technology and… Read more . . .
-
MSP, a division of TSI, has announced the launch of an enhanced Next Generation Impactor (NGI) called the NGI+, which is designed for improved resistance to corrosion and longer life expectancy. According to MSP, which… Read more . . .
-
Altimmune announced that it has submitted an investigational new drug application to the FDA for a Phase 1 clinical study of its AdCOVID intranasal COVID-19 vaccine candidate, which it is developing in partnership with the University… Read more . . .
-
Liquidia Technologies said that it has received a complete response letter in response to its NDA for LIQ861 treprostinil inhalation powder for the treatment of pulmonary arterial hypertension. The FDA accepted the 505(b)(2) NDA for… Read more . . .
-
Verona Pharma announced that it has secured up to $30 million in debt financing facility from Silicon Valley Bank for pre-commercialization activities related to the company’s nebulized ensifentrine, which is in Phase 3 development for… Read more . . .
-
Parexel announced that Synairgen has signed a collaboration agreement with Parexel Biotech for a Phase 3 trial of Synairgen’s SNG001 nebulized interferon-beta-1a for the treatment of COVID-19. In July 2020, Synairgen announced positive results from… Read more . . .
-
Adherium has announced that Monaghan Medical is set to begin a pilot program to launch Adherium’s Hailie inhaler monitoring platform in eight US respiratory centers by the end of the first quarter of 2021, with… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.